MiMedx Group Inc (MDXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MiMedx Group Inc (MDXG) has a cash flow conversion efficiency ratio of 0.123x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($29.33 Million) by net assets ($238.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MDXG cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
MiMedx Group Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MiMedx Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MiMedx Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanwha Corp Preferred
KO:00088K
|
0.032x |
|
Basler Kantonalbank
SW:BSKP
|
0.028x |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
0.014x |
|
Donegal Group A Inc
NASDAQ:DGICA
|
0.031x |
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
-0.159x |
|
Kambi Group PLC Series B
IL:0EAW
|
0.056x |
|
Clearfield Inc
NASDAQ:CLFD
|
-0.004x |
|
Empreendimentos Pague Menos S.A
SA:PGMN3
|
0.021x |
Annual Cash Flow Conversion Efficiency for MiMedx Group Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of MiMedx Group Inc from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see how much is MiMedx Group Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $193.11 Million | $66.20 Million | 0.343x | +82.72% |
| 2023-12-31 | $142.72 Million | $26.77 Million | 0.188x | +178.12% |
| 2022-12-31 | $74.51 Million | $-17.89 Million | -0.240x | -1021.73% |
| 2021-12-31 | $92.58 Million | $-1.98 Million | -0.021x | +95.03% |
| 2020-12-31 | $91.42 Million | $-39.41 Million | -0.431x | -159.80% |
| 2019-12-31 | $49.66 Million | $35.80 Million | 0.721x | 0.00% |
| 2018-12-31 | $49.66 Million | $35.80 Million | 0.721x | -15.47% |
| 2017-12-31 | $73.80 Million | $62.94 Million | 0.853x | +339.18% |
| 2016-12-31 | $133.00 Million | $25.83 Million | 0.194x | +11.51% |
| 2015-12-31 | $107.99 Million | $18.81 Million | 0.174x | -7.41% |
| 2014-12-31 | $89.33 Million | $16.80 Million | 0.188x | +4947.15% |
| 2013-12-31 | $73.57 Million | $-285.48K | -0.004x | +97.71% |
| 2012-12-31 | $20.01 Million | $-3.38 Million | -0.169x | +69.80% |
| 2011-12-31 | $11.90 Million | $-6.66 Million | -0.560x | +58.10% |
| 2010-12-31 | $6.10 Million | $-8.16 Million | -1.337x | +5.10% |
| 2009-12-31 | $6.07 Million | $-8.56 Million | -1.409x | -146.44% |
| 2008-12-31 | $14.23 Million | $-8.14 Million | -0.572x | -186.00% |
| 2007-12-31 | $-35.60K | $-23.67K | 0.665x | +109.17% |
| 2006-12-31 | $3.26K | $-23.65K | -7.250x | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more